This article is for men with metastatic castration-resistant prostate cancer (mCRPC) and their families in the Gulf region who want to access lutetium Lu-177 vipivotide tetraxetan therapy.
If you live in the UAE, Saudi Arabia, Kuwait, Qatar, Oman, or another GCC country, you may already know that Lu-177 PSMA therapy is hard to access close to home. It's also expensive where it does exist. India has offered this treatment since well before many Western countries, produces the radiopharmaceutical domestically, and charges much less than other markets. This article shows you the real costs, how quality compares at accredited centers, and what you need to know before planning travel.
What Is Lu-177 PSMA Therapy?
Lutetium Lu-177 vipivotide tetraxetan, sold under the brand name Pluvicto, is a radioligand therapy (RLT). It works by attaching a radioactive molecule, lutetium-177, to a targeting protein that seeks out PSMA (prostate-specific membrane antigen), a protein found in high amounts on most prostate cancer cells. When the molecule finds a PSMA-expressing cell, it delivers a focused dose of radiation directly to that cell while limiting damage to surrounding tissue.
This approach is part of theranostics, a field that uses the same biological target for both imaging and treatment. A PSMA-PET scan first confirms that your tumors express enough PSMA. If they do, you may be eligible for this therapy. For a fuller explanation of how it works at the molecular level, see our guide on how Lu-177 PSMA targets and treats metastatic prostate cancer.
The US FDA approved this therapy in March 2022 for men with PSMA-positive mCRPC who had already received hormone therapy and taxane-based chemotherapy. In the pivotal VISION trial, adding Lu-177 PSMA to standard care was associated with a 38% reduction in the risk of death and a 60% reduction in the risk of radiographic progression or death compared to standard care alone.
How Does Lu-177 PSMA Therapy Cost in India Compare to the UAE?
The short answer: India is substantially more affordable. Treatment at accredited Indian hospitals typically costs a fraction of the US list price, and where Lu-177 PSMA is available at private UAE hospitals, pricing tends to be significantly higher than Indian rates. The table below compares the factors that matter most to a GCC patient making this decision.
| Factor | Lu-177 PSMA in India | Lu-177 PSMA in UAE | Lu-177 PSMA in United States (reference) |
|---|---|---|---|
| Cost per cycle (2025) | Approx. USD 6,000-9,000 per cycle; varies by center and radiopharmaceutical source | Not publicly listed - varies by hospital; request a written quote | Approx. USD 42,500-50,000 per cycle (Pluvicto list price) |
| Typical full course (4-6 cycles) | Approx. USD 25,000-55,000 | Not publicly listed | Approx. USD 250,000+ at list price, before insurance |
| Access and availability | Widely available since 2017; domestic radiopharmaceutical production established | Limited to select private centers; not widely available across the UAE | Available at specialist centers; historically constrained by supply |
| Typical wait after eligibility confirmed | Often 1-3 weeks | Variable; depends on individual center capacity | Historically weeks to months due to supply and scheduling |
| Accreditation | NABH and JCI-accredited centers available at major treatment hubs | JCI-accredited major private hospitals | NCI-designated and nationally recognized cancer centers |
India cost range based on 2024-2025 estimates from Indian nuclear medicine specialist centers. US list-price figures sourced from the Drugs.com Pluvicto price guide. UAE pricing is center-specific and not publicly standardized - always request a written itemized quote before comparing.
For a GCC patient paying out of pocket, the cost difference is substantial. A full course in India may cost less than a single cycle in the United States at list price. Where Lu-177 PSMA is available in UAE private hospitals, costs are typically higher than Indian rates and generally closer to, though often below, US list prices. The potential savings from traveling to India, even after accounting for flights and accommodation, remain significant for most GCC families.
Does Lower Cost in India Mean Lower Quality?
This is the right question to ask. The honest answer is no, not at accredited specialist centers.
India was among the first countries in the world to develop domestic Lu-177 radiopharmaceutical production capacity. Indian nuclear medicine teams have delivered a large number of Lu-177 PSMA and Lu-177 DOTATATE cycles across a growing network of specialist centers. They published their results in peer-reviewed research, including a real-world analysis of Lu-177 PSMA-617 outcomes in Indian patients with metastatic prostate cancer.
The joint EANM/SNMMI procedure guideline for Lu-177 PSMA therapy sets the international standard for how treatment should be delivered, covering patient selection, radiopharmaceutical handling, dosimetry, radiation safety, and follow-up monitoring. Indian centers operating to JCI or NABH accreditation standards apply protocols consistent with these guidelines.
The key distinction is between individual centers, not countries. The questions that matter most are whether the center has a dedicated theranostics team, an active dosimetry program, experience managing the specific side effects of radioligand therapy, and a clear process for coordinating your care with your oncologist at home. Those details matter more than whether treatment happens in India or the UAE.
Who Can Get Lu-177 PSMA Therapy?
Eligibility is not automatic. You need to meet specific criteria before treatment can begin.
- Your prostate cancer must have become castration-resistant, meaning it continues to progress despite hormone therapy that suppresses testosterone.
- A PSMA-PET scan must show that your tumors express PSMA at a meaningful level. This scan is the essential eligibility step before any center can plan treatment.
- Your kidney function, bone marrow reserves, and overall fitness must be adequate for the therapy to be delivered safely.
- Most current protocols require prior treatment with at least one androgen receptor pathway inhibitor, such as enzalutamide or abiraterone. Many also require prior taxane-based chemotherapy, though this requirement is evolving as approvals expand.
The Prostate Cancer Foundation provides a clear overview of candidacy criteria for PSMA radionuclide therapy. If your PSMA-PET scan shows low or absent expression, you may not be eligible at this time. A trustworthy specialist team will say so clearly and discuss what other options remain. Our article on how international patients access Lu-177 PSMA therapy in India covers the eligibility process in more detail.
The Patient Journey for GCC Patients Traveling to India
Most patients from the Gulf region who pursue Lu-177 PSMA therapy in India follow a similar path. Knowing the steps before you start makes the process far more manageable.
Remote eligibility review. Before you travel anywhere, send your recent PSMA-PET scan, PSA history, and treatment records to a specialist team for remote review. This step confirms whether a trip makes sense for your case. It costs little or nothing and can often be completed within a few days. If you are at this stage, you can consult the Art of Healing Cancer team before travelling for treatment - they coordinate eligibility reviews and teleconsults for international patients from the GCC and other regions.
Teleconsultation. If the scan review looks encouraging, a video consultation with the nuclear medicine or oncology team allows a thorough review of your history, your questions, and any specific factors, such as kidney function or bone marrow status, that would affect how treatment is planned.
Pre-treatment workup on arrival. Once you arrive in India, a blood panel and kidney function tests confirm you are ready to proceed. This typically takes one to two days before the first infusion.
Infusion day. Each Lu-177 PSMA cycle is a single intravenous infusion, usually lasting 20-30 minutes. You remain at the center for a few hours afterward for monitoring. Most patients do not require an overnight hospital stay.
Radiation safety days. For the first few days after each cycle, you follow radiation safety precautions - maintaining distance from children and pregnant women, using separate bathroom facilities, and practicing careful hygiene. Most GCC patients stay near the treatment center for three to five days after each infusion before returning home or traveling onward.
Repeat cycles and remote follow-up. A standard course involves four to six cycles spaced roughly six weeks apart. You can return to the UAE between cycles if you prefer. Follow-up blood tests and PSA checks can often be coordinated with a local oncologist or laboratory service at home. Our article on what to monitor after your Lu-177 PSMA cycles covers the specific tests and timelines for follow-up care.
Practical Cost Planning for GCC Families
The therapy itself is the largest cost item, but not the only one to factor in. A realistic total budget for a GCC patient completing a full course in India, covering cycles, PSMA-PET eligibility scan, pre-treatment workup, accommodation near the center, and return flights from Dubai or Riyadh, typically ranges from approximately USD 30,000-65,000 for a four to six cycle course. This is a broad range because it depends on the number of cycles needed, the specific center, and accommodation choices.
For comparison, a single cycle of Pluvicto in the United States is listed at approximately USD 42,500-50,000. The financial case for traveling to India can remain strong even after all travel costs are included.
If you are also pricing UAE private hospitals, request a complete written quote that separately lists the radiopharmaceutical cost, the nuclear medicine consultation fee, the infusion administration fee, dosimetry, and follow-up imaging. In some centers these line items are quoted separately, and the total may differ substantially from an initial headline figure.
If you hold UAE health insurance, check whether your policy covers cancer treatment at internationally accredited hospitals abroad and whether radioligand therapy is specifically included. Some UAE-based insurers provide partial reimbursement at JCI-accredited Indian centers. Request written pre-authorization before you travel, not after you return.
What If Eligibility Is Not Confirmed?
Some patients who submit scans for review find that PSMA expression is too low, or that a kidney function or blood count issue makes the therapy too risky at this time. That is not the end of the road. Other treatment options include alternative hormonal agents, cabazitaxel chemotherapy, PARP inhibitor therapy for patients with certain DNA repair mutations, and clinical trials. A thorough specialist review should cover all of them, not only Lu-177 PSMA.
If you want a review of your eligibility or a second opinion on a decision you have already received, you can submit your details through the Lutetium Therapy contact form. If Lu-177 PSMA is not the right fit for your case, the review will include a discussion of what other options may be available to you.
When to Talk to Your Doctor
Talk to your oncologist or nuclear medicine specialist if your PSA continues to rise on current therapy, if you have had a recent PSMA-PET scan and want help interpreting your eligibility, if you are considering traveling for treatment and want to confirm your medical records are complete before you go, or if you have received an eligibility decision and want a second opinion on it.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
Is Lu-177 PSMA therapy available in the UAE?
A small number of private hospitals in the UAE have or are developing radioligand therapy programs, but Lu-177 PSMA therapy is not widely available across the country as a routine service. Availability varies significantly by center, and pricing is neither standardized nor publicly listed. Most GCC patients who pursue this treatment do so in India, where the therapy has been available since 2017 and is accessible at a larger number of specialist nuclear medicine centers.
How much does a full course of Lu-177 PSMA therapy cost in India for a GCC patient?
A typical course involves four to six cycles, each spaced roughly six weeks apart. Based on published 2024-2025 estimates from Indian specialist centers, the therapy itself costs approximately USD 6,000-9,000 per cycle, making a full course approximately USD 25,000-55,000 depending on the number of cycles needed. When you add return flights from the Gulf, accommodation near the treatment center, the PSMA-PET eligibility scan, and pre-treatment blood work, a realistic all-in budget is approximately USD 30,000-65,000. These are estimates - always request itemized quotes from the specific center you are considering.
Does my UAE health insurance cover Lu-177 PSMA therapy in India?
Some UAE-based health insurers cover cancer treatment at internationally accredited hospitals abroad, which can include JCI-accredited Indian centers. Whether radioligand therapy specifically is included depends on your individual policy wording. You should request written pre-authorization before you travel and be prepared to submit your oncologist's referral letter alongside a treatment plan from the Indian center. Not all policies cover this therapy category, and some require evidence that local treatment options have been exhausted first. Check your policy details and contact your insurer in writing before making any travel plans.
Do I have to stay in India for all my cycles, or can I travel home between treatments?
You can return home between cycles. Each cycle is spaced roughly six weeks apart, and most patients spend only about five to seven days in India per cycle - one to two days for the pre-cycle check, the infusion day itself, and a radiation safety period of three to five days afterward. Follow-up blood tests and PSA checks between cycles can often be coordinated with an oncologist or laboratory service in your home country, reducing the amount of time you need to spend abroad.
What is a PSMA-PET scan and do I need one before traveling to India?
A PSMA-PET scan is a specialized imaging test that detects PSMA, a protein expressed in high concentrations on most prostate cancer cells. It shows where the cancer has spread and, most importantly, whether tumors express enough PSMA to be effectively targeted by Lu-177 PSMA therapy. A recent PSMA-PET scan is generally required before treatment can be planned. If you have had one in the past several months, a specialist team can review it remotely before you commit to travel. If you have not had one, it can often be arranged in India as part of the pre-treatment workup.
How do I compare nuclear medicine centers in India when I am choosing where to have treatment?
The most important factors are whether the center has a dedicated theranostics or radioligand therapy program with a full nuclear medicine team, whether it performs dosimetry (individualized dose calculation) as part of its protocol, what its process is for coordinating follow-up with your oncologist at home, and whether it holds JCI or NABH accreditation. Published peer-reviewed outcomes data from a center is a positive indicator of experience. Avoid making your decision based on price alone - a center that is marginally cheaper but lacks dosimetry capability or a dedicated side-effect management process may not represent better value overall.